FANCD2 and ovarian cancer: This included ability to form RAD51 foci in response to ionizing radiation and chemotherapy (an indication of pathway activation downstream of FANCD2 foci formation), HR proficiency, proteasome activity, and synergism with cisplatin in both FA deficient and proficient isogenic ovarian cancer cell lines.